• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Roivant Sciences Ltd. (Amendment)

    2/14/24 11:14:48 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ROIV alert in real time by email
    SC 13G/A 1 d790270dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549 

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Roivant Sciences Ltd.

    (Name of Issuer)

    Common shares, par value $0.0000000341740141 per share

    (Title of Class of Securities)

    G76279101

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. G76279101

     

     1.   

     Names of Reporting Persons.

     

     QVT Financial LP

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     112,541,536

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     112,541,536

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     112,541,536

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     13.97%

    12.  

     Type of Reporting Person (See Instructions)

     

     PN


    CUSIP No. G76279101

     

     1.   

     Names of Reporting Persons.

     

     QVT Financial GP LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     112,541,536

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     112,541,536

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     112,541,536

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     13.97%

    12.  

     Type of Reporting Person (See Instructions)

     

     OO


    CUSIP No. G76279101

     

     1.   

     Names of Reporting Persons.

     

     QVT Financial Investment Cayman Ltd.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     34,430,591

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     34,430,591

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     34,430,591

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     4.27%

    12.  

     Type of Reporting Person (See Instructions)

     

     CO


    CUSIP No. G76279101

     

     1.   

     Names of Reporting Persons.

     

     QVT Roiv Hldgs Offshore Ltd.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     34,830,463

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     34,830,463

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     34,830,463

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     4.32%

    12.  

     Type of Reporting Person (See Instructions)

     

     CO


    Item 1(a).    Name of Issuer
       Roivant Sciences Ltd. (the “Issuer”)
    Item 1(b).    Address of Issuer’s Principal Executive Offices
       The address of the Issuer’s principal executive offices is:
       7th Floor, 50 Broadway, London SW1H 0DB, United Kingdom
    Item 2(a).    Name of Person Filing
    Item 2(b).    Address of Principal Business Office or, if none, Residence
    Item 2(c).    Citizenship
      

    QVT Financial LP

      

    888 Seventh Avenue, 43rd Floor

      

    New York, New York 10106

      

    Delaware Limited Partnership

      

    QVT Financial GP LLC

      

    888 Seventh Avenue, 43rd Floor

      

    New York, New York 10106

      

    Delaware Limited Liability Company

      

    QVT Financial Investment Cayman Ltd.

      

    1 Nexus Way

      

    Camana Bay

      

    George Town, Grand Cayman, KY1 9005 Cayman Islands

      

    Cayman Islands Limited Company

      

    QVT Roiv Hldgs Offshore Ltd.

      

    1 Nexus Way

      

    Camana Bay

      

    George Town, Grand Cayman, KY1 9005 Cayman Islands

      

    Cayman Islands Limited Company

    Item 2(d).    Title of Class of Securities
       Common shares, par value $0.0000000341740141 per share (the “Common Shares”)
    Item 2(e).    CUSIP Number
       The CUSIP number of the Common Stock is G76279101.


    Item 3.      If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a)   

    ☐   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

      (b)   

    ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

      (c)   

    ☐   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

      (d)   

    ☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

      (e)   

    ☐   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

      (f)   

    ☐   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

      (g)   

    ☐   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

      (h)   

    ☐   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

      (i)   

    ☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

      (j)   

    ☐   A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

      (k)   

    ☐   Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____.

    Item 4.      Ownership.
      (a)    Amount beneficially owned:
         Aggregately, QVT Financial LP (“QVT”) may be deemed to be the beneficial owner of 112,541,536 Common Shares, consisting of the Common Shares owned by QVT Roiv Hldgs Onshore Ltd. and QVT Roiv Hldgs Offshore Ltd. (together, "QVT Roiv"), Fourth Avenue Capital Partners LP (“Fourth Avenue”), QVT P&E Roiv Hldgs Ltd. (“QVT P&E”), QVT Deferred Compensation Holdings Ltd (“QVT DCH”) and QVT Financial Investment Cayman Ltd. (“QVT FIC”). QVT Financial GP LLC (“QVT Financial GP”) is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT.
         QVT is the investment manager of QVT Roiv, shares voting and investment control over the Common Shares held directly by QVT Roiv and therefore may be deemed to beneficially own such Common Shares.
         QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own, the Common Shares held by Fourth Avenue, QVT P&E, QVT DCH and QVT FIC; QVT disclaims beneficial ownership of such Common Shares. Management of Fourth Avenue is vested in its general partner, Fourth Avenue Capital Partners GP LLC, a Delaware limited liability company, which may be deemed to beneficially own the Common Shares held directly by Fourth Avenue.
         The percentage disclosed in Item 11 of the Cover Pages for each reporting person is calculated on the basis of 805,846,006 Common Shares outstanding, as reported by the Issuer in its Form 10-Q for the quarterly period ended December 31, 2023, as filed with the Securities and Exchange Commission on February 13, 2024.


      (b)

    Percent of class:

    See Item 11 of the Cover Pages to this Schedule 13G.

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote

    0

     

      (ii)

    Shared power to vote or to direct the vote

    See item (a) above.

     

      (iii)

    Sole power to dispose or to direct the disposition of

    0

     

      (iv)

    Shared power to dispose or to direct the disposition of

    See item (a) above.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    As of December 31, 2023, each of QVT Financial Investment Cayman Ltd. and QVT Roiv Hldgs Offshore Ltd. ceased to be the beneficial owner of more than five percent of the class of securities.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not Applicable

     

    Item 8.

    Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9.

    Notice of Dissolution of Group

    Not Applicable

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024    
    QVT FINANCIAL LP     QVT ROIV HLDGS OFFSHORE LTD.

    By QVT Financial GP LLC,

    its General Partner

       
    By:   /s/ Meg Eisner     By:   /s/ Meg Eisner
    Name:   Meg Eisner     Name:   Meg Eisner
    Title:   Authorized Signatory     Title:   Authorized Signatory
    QVT FINANCIAL GP LLC     QVT FINANCIAL INVESTMENT CAYMAN LTD
    By:   /s/ Meg Eisner     By:   /s/ Meg Eisner
    Name:   Meg Eisner       Name:   Meg Eisner
    Title:   Authorized Signatory     Title:   Authorized Signatory
    Get the next $ROIV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ROIV

    DatePrice TargetRatingAnalyst
    2/15/2024$17.00Outperform
    Wolfe Research
    1/5/2024$20.00Overweight
    Piper Sandler
    12/12/2023$14.00Buy
    Deutsche Bank
    10/17/2023$17.00Buy
    Guggenheim
    6/8/2023$10.50Neutral
    BofA Securities
    10/27/2022$7.00Overweight
    JP Morgan
    5/23/2022$6.00Outperform
    SVB Leerink
    4/29/2022$15.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ROIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

      SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      11/14/24 4:31:06 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

      SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      11/12/24 4:58:58 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Roivant Sciences Ltd.

      SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)

      11/12/24 10:34:18 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

      BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to report its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conferen

      5/15/25 4:10:00 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

      Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant  IND cleared for a potentially registrational program for IMVT-1402 in SjD, its fifth and potentially best-in-class indication with positive in-class competitor data from Phase 2 studies suggesting a correlation between depth of IgG reduction and degree of clinical improvement; study expected to initiate in summer 2025Proof-of-concept study of

      4/21/25 7:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction) Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70% In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepoints INDs active for both MG and C

      3/19/25 7:45:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Pulik Richard covered exercise/tax liability with 3,487 shares, decreasing direct ownership by 0.86% to 402,212 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      5/22/25 9:00:39 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & COO Venker Eric covered exercise/tax liability with 39,148 shares, exercised 100,000 shares at a strike of $3.85 and sold $1,095,000 worth of shares (100,000 units at $10.95), decreasing direct ownership by 4% to 1,077,197 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      5/22/25 9:00:37 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Gline Matthew covered exercise/tax liability with 10,945 shares, decreasing direct ownership by 0.06% to 17,283,766 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      5/22/25 9:00:36 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

      SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      5/15/25 6:53:25 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

      SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      5/15/25 5:29:42 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

      SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      5/15/25 4:35:35 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on Roivant Sciences with a new price target

      Wolfe Research initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $17.00

      2/15/24 6:44:53 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Roivant Sciences with a new price target

      Piper Sandler initiated coverage of Roivant Sciences with a rating of Overweight and set a new price target of $20.00

      1/5/24 8:43:06 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Roivant Sciences with a new price target

      Deutsche Bank initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $14.00

      12/12/23 8:08:23 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Financials

    Live finance-specific insights

    See more

    $ROIV
    Leadership Updates

    Live Leadership Updates

    See more
    • Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

      BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to report its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conferen

      5/15/25 4:10:00 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

      Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant  IND cleared for a potentially registrational program for IMVT-1402 in SjD, its fifth and potentially best-in-class indication with positive in-class competitor data from Phase 2 studies suggesting a correlation between depth of IgG reduction and degree of clinical improvement; study expected to initiate in summer 2025Proof-of-concept study of

      4/21/25 7:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction) Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70% In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepoints INDs active for both MG and C

      3/19/25 7:45:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

      NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In

      3/26/24 6:22:00 PM ET
      $PGTI
      $ROIV
      $RUN
      $SPGI
      Building Products
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

      BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue

      11/10/23 8:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer

        BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry. With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-depth experience in immunology therapies, Vincent is poised to guide Covant Therapeutics into a new era of growth, innovation, and patient-centric excellence. Vincent joins Covant Therapeutics from his previous role as COO at Intergalactic T

      10/13/23 8:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care